Physician profile
Emerald Lassiter
NPI 1942911953
$2,655.41
in general payments reported to CMS, 2019-2025
26 companies · $1,735 in 2025
The $1,735 reported for 2025 was more than what 95% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $921 · 2025: $1,735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,257 · Travel and Lodging: $264 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,256.55 |
| Travel and Lodging | $263.80 |
| Education | $135.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $316.66 | 2024-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $303.08 | 2024-2025 | |
| Medtronic, INC. | $263.80 | 2025 | Interstim |
| Janssen Biotech, INC. | $246.34 | 2024-2025 | Erleada, Akeega |
| Bayer Healthcare Pharmaceuticals INC. | $199.80 | 2025 | |
| Urogen Pharma, INC. | $181.71 | 2024-2025 | |
| Abbvie INC. | $159.45 | 2025 | |
| Progenics Pharmaceuticals, INC. | $123.66 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $115.75 | 2024-2025 | Adstiladrin |
| Intuitive Surgical, INC. | $100.00 | 2024 | |
| Merck Sharp & Dohme LLC | $71.22 | 2024-2025 | Keytruda |
| C. R. Bard, INC. & Subsidiaries | $69.69 | 2025 | Bard Urinary Drainage Bag |
| Endo USA, INC. | $62.22 | 2024-2025 | Xiaflex, Aveed |
| Novartis Pharmaceuticals Corporation | $56.16 | 2024-2025 | |
| Boston Scientific Corporation | $54.88 | 2024-2025 | Axonics, Ams 700, Spaceoar Vue System - 10ml |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $53.33 | 2024-2025 | Xtandi |
| Becton, Dickinson and Company | $41.73 | 2024 | Bard Urinary Drainage Bag |
| Cycle Pharmaceuticals INC | $39.28 | 2025 | Venxxiva |
| Astrazeneca Pharmaceuticals Lp | $35.06 | 2025 | Imfinzi |
| Myriad Genetic Laboratories, INC. | $32.12 | 2024 | Prolaris |
| Dendreon Pharmaceuticals LLC | $31.92 | 2024 | Provenge |
| 180 Medical, INC. | $26.13 | 2024 | Cure Twist |
| Coloplast Corp | $22.08 | 2024 | |
| Axonics, INC. | $19.69 | 2024 | Axonics |
| Laborie Medical Technologies Corp. | $15.07 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Ambu INC. | $14.58 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emerald Lassiter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.